Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 144

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 144
---
 below and in the footnotes thereto.

84

Share Option and Incentive Plans

Company Option and Incentive
Plans

We maintain four share option and incentive plans: Evogene Ltd.
2002 Share Option Plan, Evogene Ltd. 2003 Key Employee Share Incentive Plan, Evogene Ltd. 2013 Share Option Plan, and Evogene Ltd. 2021
Share Incentive Plan, or the 2021 Plan. No new grants will be made under the first three plans, although outstanding awards under those
plans remain subject to the terms of those plans. All such option and incentive plans provide for the grant of options to purchase our
ordinary shares, and the 2021 Plan also provides for the issuance of restricted shares, the grant of RSUs and the issuance or grant of
other equity-based awards.

On November 20, 2024, the Board approved an
increase of 337,090 ordinary shares issuable pursuant to the 2021 Plan. As of March 17, 2025, options to purchase 772,974ordinary shares,
having a weighted average exercise price of $14.07 per share, and 16,070 RSUs, having no exercise price, were outstanding under our option
and incentive plans, and options to purchase 338,634 ordinary shares were exercisable and 32,685 RSUs were vested. An additional 88,326
ordinary shares remained available for future grant under our 2021 Plan as of that date.

Among other types of equity-based awards, our share option and
incentive plans provide for granting awards in compliance with Section 102 of the Israeli Income Tax Ordinance [New Version], 5721-1961,
or the Tax Ordinance, which provides to employees, directors and officers, who are not controlling shareholders ( i. e.,
who hold less than 10% of our share capital) and are Israeli residents, favorable tax treatment for compensation in the form of shares,
options, RSUs or other types of equity awards issued or granted, as applicable, to a trustee under the “capital gains track”
for the benefit of the relevant employee, director or officer and are held by the trustee for at least two years after the date of grant
or issuance. Under the “capital gains track”, we are not allowed to deduct an expense with respect to the grant or issuance
of the relevant equity-based awards.

The 2021 Plan also permits us to grant equity-based awards to